RETA · Reata Pharmaceuticals Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $2.22M | $11.49M | $9.02M | $26.52M | $49.86M | $48.06M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $169.84M | $155.99M | $159.08M | $128.11M | $97.29M | $71.27M |
| SG&A | $109.28M | $99.00M | $75.13M | $58.30M | $32.75M | $23.26M |
| Total Operating Expenses | $280.25M | $256.20M | $235.34M | $311.74M | $130.47M | $94.97M |
| D&A | $1.13M | $1.20M | $1.14M | $932.0K | $431.0K | $437.0K |
| Operating Income | ($311.93M) | ($297.84M) | ($270.24M) | ($290.16M) | ($80.52M) | ($47.67M) |
| Interest Expense | $0 | $6.56M | $14.89M | $11.20M | $6.18M | $1.45M |
| Income Tax | ($25.0K) | ($450.0K) | ($22.49M) | $8.0K | $26.0K | $3.0K |
| Net Income | ($311.90M) | ($297.39M) | ($247.75M) | ($290.17M) | ($80.55M) | ($47.67M) |
| EPS - Basic | ($8.54) | ($8.19) | ($7.35) | ($9.54) | ($2.91) | ($1.99) |
| EPS - Diluted | ($8.54) | ($8.19) | ($7.35) | ($9.54) | ($2.91) | ($1.99) |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $42.31M | $590.26M | $818.15M | $664.32M | $337.79M | $129.78M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $18.71M | $13.51M | $4.79M | $1.91M | $4.47M | $2.07M |
| Current Assets | $397.77M | $596.48M | $847.34M | $669.28M | $342.27M | $133.11M |
| Total Assets | $514.49M | $735.02M | $857.60M | $682.42M | $345.21M | $135.34M |
| Current Liabilities | $58.96M | $53.99M | $119.20M | $192.01M | $55.92M | $47.62M |
| Long-term Debt | - | - | $0 | $155.02M | $79.22M | $18.39M |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | ($65.69M) | $185.99M | $417.43M | $256.86M | $15.16M | ($146.97M) |
| Retained Earnings | ($1.57B) | ($1.26B) | ($958.25M) | ($710.49M) | ($420.32M) | ($337.14M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($204.27M) | ($235.70M) | ($322.34M) | ($251.15M) | ($19.26M) | ($83.26M) |
| Investing Cash Flow | ($345.16M) | ($1.33M) | ($927.0K) | ($2.67M) | ($339.0K) | ($343.0K) |
| Financing Cash Flow | $1.49M | $9.14M | $477.09M | $580.36M | $62.32M | $128.65M |
| CapEx | $3.27M | $1.33M | $927.0K | $2.67M | $679.0K | $344.0K |
| Free Cash Flow | ($207.54M) | ($237.03M) | ($323.27M) | ($253.82M) | ($19.94M) | ($83.60M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -14076.1% | -2592.1% | -2996.3% | -1094.2% | -161.5% | -99.2% |
| EBITDA margin | -14025.1% | -2581.7% | -2983.7% | -1090.7% | -160.6% | -98.3% |
| Net margin | -14075.0% | -2588.2% | -2747.0% | -1094.3% | -161.6% | -99.2% |
| Free cash flow margin | -9365.4% | -2062.9% | -3584.3% | -957.2% | -40.0% | -174.0% |
| FCF / Net income | 0.67 | 0.80 | 1.30 | 0.87 | 0.25 | 1.75 |
| R&D / Revenue | 7664.4% | 1357.6% | 1763.8% | 483.1% | 195.1% | 148.3% |
| SG&A / Revenue | 4931.3% | 861.6% | 833.0% | 219.9% | 65.7% | 48.4% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -60.6% | -40.5% | -28.9% | -42.5% | -23.3% | -35.2% |
| Return on equity | 474.8% | -159.9% | -59.4% | -113.0% | -531.3% | 32.4% |
| Return on invested capital | - | - | -51.1% | -55.7% | -67.4% | - |
| Liquidity | ||||||
| Current ratio | 6.75 | 11.05 | 7.11 | 3.49 | 6.12 | 2.80 |
| Quick ratio | 6.75 | 11.05 | 7.11 | 3.49 | 6.12 | 2.80 |
| Cash ratio | 0.72 | 10.93 | 6.86 | 3.46 | 6.04 | 2.73 |
| Leverage | ||||||
| Debt / Equity | - | - | 0.00 | 0.60 | 5.23 | -0.13 |
| Debt / Assets | - | - | 0.00 | 0.23 | 0.23 | 0.14 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | -45.4x | -18.1x | -25.9x | -13.0x | -32.8x |
| Equity multiplier | -7.83 | 3.95 | 2.05 | 2.66 | 22.77 | -0.92 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | 0.00 | 0.02 | 0.01 | 0.04 | 0.14 | 0.36 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -80.7% | 27.4% | -66.0% | -46.8% | 3.7% | -3.6% |
| Revenue CAGR (3y) | -56.3% | -38.7% | -42.7% | -19.0% | - | - |
| Revenue CAGR (5y) | -46.0% | -25.4% | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -4.7% | -10.2% | 6.9% | -260.4% | -68.9% | -614.9% |
| Net income growth (YoY) | -4.9% | -20.0% | 14.6% | -260.3% | -69.0% | -665.6% |
| EPS growth (YoY) | -4.3% | -11.4% | 23.0% | -227.8% | -46.2% | -541.9% |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 12.4% | 26.7% | -27.4% | -1173.1% | 76.2% | -326.6% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | -55.4% | 62.5% | 1594.4% | - | 31.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$11.49M totalLicense And Service$8.04M · 70.0%
Service Other$3.45M · 30.0%
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing REATA PHARMACEUTICALS INC against the 5 most active filers in the same SIC group.